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Abstract. We performed a prospective analysis of two consecutive biopsy
cohorts investigated by the same team to compare the Mammotome
system with the ABBI procedure. From April 1997 to August 2003 a series
of 413 nonpalpable mammographic lesions in 387 women (median age 56
years, range 30–84 years) were stereotactically biopsied in the University
Hospital of Basel, Switzerland. Until October 1999 the ABBI system was
applied exclusively, it was subsequently superseded by the Mammotome
device in our clinic. Main outcome measures were accuracy, technical
demand, and morbidity. Sensitivity (97.3%/96.8%), negative predictive
value (99.2%/98.7%), and diagnostic accuracy (99.4%/99.1%) regarding
the detection of malignancy were excellent for both techniques (ABBI/
Mammotome). The Mammotome procedure was faster and less invasive,
thus causing significantly less morbidity. The larger specimen obtained by
the ABBI procedure resulted in more detailed histology. In conclusion,
recommend the Mammotome system as the method of choice for detecting
nonpalpable early breast cancer.
The biopsy of nonpalpable suspicious radiopaque breast lesions is
a challenging procedure carried out by mammographically or
sonographically guided techniques. The advanced breast biopsy
instrumentation (ABBI; United States Surgical Corporation,
Norwalk, CT, USA) as one of the first stereotactically imaging
instruments has been established with high accuracy [1–11]. Dis-
advantages of this method are its time-consuming complexity and
the residual scar, with a length of 10 to 30 mm depending on the
caliber of the cutting cannula used. Subsequently, the stereotactic
vacuum-assisted core breast biopsy (Mammotome, Ethicon Endo-
Surgery, Cincinnati, OH, USA) has successfully been introduce
[11, 17–17]. The aim of this study was to assess the Mammotome
system and to compare its accuracy, technical demand, and
morbidity to that of the ABBI procedure performed in a con-
secutive series of patients by the same investigating team.
Patients and Methods
From April 1997 we entered the histologic findings and follow-up
data of all patients with an ABBI biopsy in our hospital pro-
spectively into a spreadsheet database (Excel, Microsoft). The
Mammotome system was introduced in our clinic during October
1999. After an initial training period of 5 months during which
still 19 ABBI procedures were performed, all stereotactically
guided biopsies were carried out using the Mammotome system.
Consecutive data from patients biopsied until August 2003 were
included in the study. Indications for a stereotactic biopsy were
mammographically suspicious, but impalpable breast lesions
according to BIRADS III–V. There was no further selection of
patients. The ABBI procedure was performed as earlier described
[1, 5, 8, 18, 19–5, 8, 18, 19]. Its oscillating blade-cutting cannula
produces one large cylinder of the suspicious breast tissue with
sharp margins. These excisional biopsies and the following doc-
umentation of data were performed by the same team of expe-
rienced surgeons and gynecologists with their registrars in our
hospital.
The Mammotome technique, as previously described [2, 12, 16],
using the same stereotactically guided interventionist table (Lorad
stereoguide table; LoRad, Danbury, CT, USA) achieves a repre-
sentative specimen by multiple tissue cores obtained by vacuum
suction in a circumferential manner. Therefore an 11-gauge biopsy
needle is inserted under stereotactic guidance. Because the
Mammotome allows a less invasive procedure to be performed, a
few specialized radiologists joined our interventional diagnostic
team.
During all stereotactic procedures the site of lesion was marked
with a metal clip to allow easy relocalization for further treatment
if required. Removal of the suspicious lesion was documented by
radiography of the resected specimen in combination with a ste-
reotactic mammogram of the excisional site immediately after the
biopsy was performed. All histologic diagnoses were confirmed by
a second pathologist. The incision after ABBI procedures wasCorrespondence to: Walter R. Marti, M.D., e-mail: wrmarti@uhbs.ch
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closed by interrupted sutures, and the stab incision after Mam-
motome biopsies was closed simply by SteriStrips. A compressive
bandage left for 24 hours to prevent excessive hematoma and
removal of the skin sutures or SteriStrips after 5 days combined
with a discussion of the histologic findings completed the inves-
tigation. All stereotactic biopsies were performed under local
anesthesia on an outpatient basis.
Whenever possible, a malignant lesion was treated by breast-
conserving tumorectomy followed by adjuvant radiotherapy and
systemic therapy if indicated. Patients with benign lesions were
followed according to the referring physicians concept of optimal
prevention appropriate to the individual risk for breast cancer.
Women with benign lesions and a low risk were routinely advised
to undergo clinical examination and mammography with or
without sonography every other year on a screening basis from
age 50 up to the age of 69. The patient’s histopathologic findings
and follow-up data after definitive treatment of malignant find-
ings were entered prospectively into a database (Excel, Microsoft
Access Database Software; Microsoft, Redmond, WA, USA).
Follow-up data for patients with benign lesions were obtained
from the patients themselves and their attending physicians.
Morbidity was assessed using a standardized questionnaire. We
addressed the patients subjective experience during the investi-
gation, followed by a series of questions pointing at wound
healing and their long-term course.
The diagnostic characteristics of the two techniques were
evaluated by compariaon of the biopsy results with the definitive
pathologic diagnosis and by analyzing the follow-up data on be-
nign lesions. Mammographic/sonographic examination were per-
formed in 93% (111/120)/88% (106/120) of the patients with a
benign ABBI result, whereas 78% (117/150)/76% (114/150) of the
patients in the Mammotome cohort have had at least one radio-
logic reassessment of the breast since the biopsy. Most of the
patients without imaging follow-up are young women with low
risk for breast cancer not yet qualifying for screening mammog-
raphy. All patients had at least one clinical investigation of the
breast since the biopsy, the latest after a median follow-up of 5.2
years (range 3.8–6.7 years) for the ABBI cohort and 2.1 years
(range 0.5–4.4 years) for the Mammotome series. Follow-up data
on an additional 5 benign ABBI biopsies and 12 benign Mam-
motome biopsies were not available for analysis.
The unpaired t-test was used for comparisons of continuous
outcomes, and Fishers exact test was used for comparisons of
dichotomous and categoric variables. Statistical significance was
defined below an a level of p = 0.05. All statistical tests were two-
sided. Statistical analyses were performed by GraphPad InStat
software version 3.05 (GraphPad Software, San Diego, CA,
USA).
Results
Indications for 413 consecutive stereotactic breast biopsies in 387
women were 331 cases of microcalcifications, 61 nodular masses,
and 21 other mammographically suspicious and nonpalpable le-
sions. Irrespective of the technique applied, 93% of the biopsies
were performed successfully (Table 1). The median duration of
the Mammotome procedure was significantly shorter (p <
0.0001).
Most of the biopsy procedures were well tolerated in both
series. However, a small number of patients complained about
severe pain despite further injection of local anesthetic (seven
patients in each cohort, including two for procedures that had to
be interrupted because of pain in the ABBI series and one in the
Mammotome group). Three patients were treated by both tech-
niques. They mentioned no preferences for one or the other, and
the durations of the two procedures were comparable.
Surgical complications were rare and mild (Table 2). The
morbidity rate after a Mammotome biopsy was significantly lower
than after an ABBI procedure (p < 0.022). The scar was readily
accepted by most of the patients.
The rate of malignancy was comparable in the two groups and
within the range of various recently published consecutive series
of stereotactic breast biopsies [3, 9, 11, 15, 17]. The detected
histologic findings are outlined in Table 3.
Sensitivity, negative predictive value, and diagnostic accuracy
were excellent for both types of biopsy (Table 4). One invasive
lobular carcinoma was sonographically detected in the clip-
marked area of the breast 3 months after a false-negative ABBI
biopsy that revealed nonsuspicious tissue. In the Mammotome
series two malignant lesions were missed: In the first case the
biopsy of suspicious microcalcification demonstrated fibrotic
changes, but the presence of only minimal calcareous traces on
radiography of the resected specimen initiated further investiga-
tions. After 4 months mammography showed virtually unchanged
microcalcification compared to the prebiopsy image. A second
Mammotome procedure resulted in the diagnosis of a low-grade
ductal carcinoma in situ (DCIS) treated by tumorectomy; a third
Mammotome biopsy in the same breast 1 year later uncovered a
multicentric DCIS, and finally a mastectomy was necessary. In the
second case the patient had breast-conserving therapy and axillary
treatment of an invasive carcinoma (pT2pN1cM0 G3 R0) fol-
lowed by bilateral reduction mammoplasty for cosmetic reasons.
Table 1. Patients and technical data.
Parameter ABBI Mammotome
Study period April 1997 to March 2000 October 1999 to August 2003
Median age (years) 56.2 (33–78) (159 patients) 56.1 (30–84) (228 patients)
Nonpalpable, suspicious lesions (n = 413) 174 239
Successful biopsies 162 (93%) 223 (93%)
Breast too small/lesion too close to the chest wall 5 (2.9%) 5 (2.1%)
Lesion not evident on image 5 (2.9%) 8 (3.3%)
Biopsy refused/discontinuation because of pain 2 (1.1%) 1 (0.4%)
Technical problems 0 2 (0.8%)
Median duration (minutes)* 90(50–180) 60(30–150)
Demographic and technical data of 413 Consecutive Stereotacric breast biopsies in 387 women
*p < 0.0001.
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Four years later a Mammotome biopsy that revealed architectural
and calcareous distortion in the same area of the breast showed
only microcalcification and scar tissue. In a familial high-risk
situation the magnetic resonance tomographic examination 4
months later was still suspicious of cancer. A wide, open biopsy
proved local recurrence of the invasive carcinoma, and the pro-
cedure had to be completed with a mastectomy.
After surgical treatment we recorded a histopathologic under-
estimate of the malignant disease by the biopsy result in seven
patients in whom the invasive component was missed by the ste-
reotactic procedure (Table 4). Six of those biopsies uncovering
only the in situ component were carried out using the incisional
Mammotome technique. After tumorectomy, all seven patients
had to be rescheduled for axillary staging by the sentinel lymph
node procedure.
During the study period, 10 cases of atypical ductal or lobular
hyperplasia (ADH/ALH) and four cases of lobular carcinoma in
situ (LCIS) were observed as borderline lesions during an
intensive follow-up, particularly a sonographic and clinical
examinations every 6 months combined with mammography once
a year. In one case the Mammotome biopsy showed ADH and
ALH in combination with an LCIS. These findings in a familial
Table 2. Morbidity.
Morbid condition ABBI (n = 120/125)
a p Mammotome (n = 150/162)a
Wound infection 1 (0.8%) 1.00 2 (1.3%)
Skin lesion 2 (1.7%) 0.20 0
Severe bruising/seromatb 5 (4.2%) 0.76 5 (3.3%)
Persistent pain/discomfort 4 (3.3%) 0.41 2 (1.3%)
Incomplete satisfaction with the cosmetic result 8 (6.7%) 0.03 2 (1.3%)
Total 20 (16.7%) 0.02 11 (7.3%)
Morbidity was assessed by collecting the follow-up data of 270 patients with benign lesions and no further surgical intervention of the breast from
the patients themselves and their attenting physicians using a standardized questionnaire.
Overall morbidity was significantly less in the Mammotome series (p = 0.021, Fishers exact test).
aFollow-up data of 5 additional benign ABBI and 12 benign Mammotome biopsies were not available for analysis.
bRequiring interventional therapy or conservative treatment over a period of several months.
Table 3. Histopathologic findings.
Histopathologic ﬁnding ABBI (n = 162) Mammotome (n = 223)
Malignant lesions 37 (22.8%) 61 (27.4%)
Invasive cancer
Ductal only 3 12
Ductal and ductal in situ 8 6
Lobular only 1 1
Lobular and lobular or ductal in situ 1 1
Tubular with or without ductal in situ 3 1
Mucinous 1 —
Carcinoma in situ
Ductal only 17 40
Ductal and lobular 3 —
Benign lesionsa 125 (77.2%) 162 (72.6%)
Mastopathy/benign proliferative changes 81 93
Fibrosis/scar tissue 24 45
Fibroadenoma 13 15
Borderline lesions
Papilloma 1 1
Atypical ductal or lobular hyperplasia/lobular carcinoma in situ 6 8
Analysis of the histopathologic findings of all 385 successfully performed stereotactic breast biopsies.
aThe main component of mixed benign lesions was recorded.
Table 4. Characteristics of Mammotome versus ABBI regarding the detection of malignancy.
Characteristic ABBI (n = 157)
a p Mammotome (n = 211)a
Sensitivity 97.3% (37/38) 96.8% (61/63)
Negative predictive value 99.% (119/120) 98.7% (148/150)
Diagnostic accuracy 99.4% (156/157) 99.1% (209/211)
In situ component missed 3 1.00 6
Invasive component missedb 1 0.22 6
The biopsy results were compared with the definitive histopathologic diagnosis and a median follow-up time for benign lesions of 2.1 years (range
0.5–4.4 years) and 5.2 years (range 3.8–6.7 years), respectively, for the Mammotome versus the ABBI techniques.
aFollow-up data of 5 additional benign ABBI and 12 benign Mammotome biopsies were not available for analysis
bReintervention after initial surgery was necessary for axillary staging.
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risk situation were considered an indication for follow-up surgical
excision, which revealed both a mixed invasive ductal and lobular
carcinoma next to the atypical hyperplasia and LCIS. During
follow-up of all other 13 atypical hyperplasia and LCIS cases, no
upstaging was necessary.
Discussion
First we evaluated our ABBI system with specific regard to its po-
tential therapeutic use [20]. The percentage of incompletely excised
malignant lesions was 84% (26/31). The final evaluation of the
ABBI series revealed that the proportion of biopsy margins infested
with malignancy remained unchanged (data not shown). Several
other published series showed a similar limitation [1, 6, 19], advo-
cating that the ABBI procedure should not be used routinely for
therapeutic purposes.
Subsequently, this excisional procedure was superseded in our
hospital by an even less invasive stereotactic technique, the inci-
sional vacuum-assisted core breast biopsy (Mammotome), with
the expectation of comparable diagnostic accuracy.
The identical median age of the patients and the similar rate of
malignancy in our two series suggest an equal indication for the
two techniques in our hospital. Thus the two series investigated by
the same medical team are comparable even though the ABBI
population is a historical control. Moreover, our rate of malig-
nancy is comparable to that in several published stereotactic
biopsy series [3, 9, 11, 15, 17].
Our 7.1% (1/14) rate of upstaging ADH or lobular neoplasia
(ALH/LCIS) detected by the Mammotome to a DCIS or an
invasive carcinoma during follow-up is within the published range
of 0% to 25% [21–24]. There is a common trend in the literature
toward routine surgical excision of ADH detected by stereotactic
procedures to ensure adequate staging [21–23, 25–30]; however,
some authors still disagree because of the many cases of unnec-
essary removal of these lesions [24, 31, 32]. Likewise, the standard
procedure after diagnosis of lobular neoplasia (ALH/LCIS) by
the Mammotome is still controversial. Although routine surgical
excision of lobular neoplasia has lately been recommended [30],
most authors demand additional risk factors for a subsequent
open biopsy [33–37]. In the absence of additional indications for
open biopsy, such as radial scar, phylloides tumor, intraductal
papilloma, or a strong personal or familial history for breast
cancer, we followed patients with these borderline lesions more
intensively.
The more invasive excisional ABBI technique achieved a larger
specimen with sharp margins resulting in a more detailed histo-
logic diagnosis; thus only one malignancy and one invasive com-
ponent were missed in this cohort. This turned out to be the only
clear advantage of the ABBI system in our comparison, although
the difference was statistically not significant (p > 0.05).
New developments such as the larger 8-gauge needle and a new
11-gauge stereo probe for the Mammotome might negate this
deficiency. In contrast, the incisional Mammotome technique
caused significantly less morbidity. In addition, the necessary
therapeutic reexcision of the residual tunnel after an ABBI biopsy
to ensure complete removal of the tumor is demanding and re-
sults in large tissue loss. Although the Mammotome is a chal-
lenging technique that requires a specialized team for an
appropriate indication and precise performance, it is the less
complex procedure, is more rapidly performed, and is at least
equally tolerated compared to the ABBI technique. As its accu-
racy for the detection of malignancy is similar, we recommend the
Mammotome system as the method of choice for detecting non-
palpable early breast cancer.
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